Page last updated: 2024-08-24

nelfinavir and HIV

nelfinavir has been researched along with HIV in 47 studies

*HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. [MeSH]

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (21.28)18.2507
2000's34 (72.34)29.6817
2010's3 (6.38)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR1
Furfine, ES; Hanlon, MH; Hazen, RJ; Miller, JF; Ray, JA; Robinson, L; Samano, V; Spaltenstein, A1
Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A1
Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Kimura, T; Kiso, Y; Nakahara, K; Nakatani, S; Nguyen, JT; Sato, A1
Barreca, ML; Benkestock, K; Chimirri, A; Christ, F; De Luca, L; Debyser, Z; Eneroth, A; Ferro, S; Hombrouck, A; Johansson, NG; Michiels, M; Noppe, W; Sahlberg, BL; Van Remoortel, B; Vrang, L; Witvrouw, M1
Baptista, LPR; Branquinha, MH; Castilho, VVS; d'Avila-Levy, CM; Gonçalves, KCS; Guimarães, AC; Menna-Barreto, RFS; Rebello, KM; Sangenito, LS; Santos, ALS; Santos, HLC1
Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K1
Krauchenco, S; Martins, NH; Polikarpov, I; Sanches, M1
Asensi, V; Cartón, JA; Collazos, J1
Ellis, GM; Frenkel, LM; Hitti, J; Huang, S1
Biasin, M; Clerici, M; Di Pietro, M; Lo Caputo, S; Maserati, R; Mazzotta, F; Ravasi, G; Seminari, E; Trabattoni, D1
Berenguer, J; Casas, E; Castro, A; de Mendoza, C; López-Calvo, S; Núńez, M; Podzamczer, D; Rosón, B; Rubio, A; Soriano, V; Valer, L1
Piliero, P; Sanne, I; Schnittman, S; Squires, K; Thiry, A1
Bergshoeff, AS; Burger, DM; Geelen, SP; Wolfs, TF1
Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M1
Calza, L; Chiodo, F; Manfredi, R1
Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Geelen, SP; van Rossum, AM; Wolfs, TF1
Bouvet, E; Chêne, G; Cottalorda, J; de Boever, CM; Journot, V; Le Moing, V; Leport, C; Peytavin, G; Préau, M; Raffi, F1
Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D1
DeGoey, DA; Randolph, JT1
Bond, SJ; Sarah Walker, A; White, IR1
Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P1
Back, DJ; Cane, P; Chandler, B; Detsika, MG; Khoo, SH; Owen, A; Winstanley, C1
Back, DJ; Cane, PA; Chandler, B; Detsika, M; Evans, S; Hartkoorn, RC; Khoo, SH; Owen, A1
Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D1
Baker, R; Brooks, JT; Hoffman, M; Moorman, A; Novak, R; Uy, J1
Ahle, D; Bushnell, S; Chang, C; Collins, ML; Detmer, J; Fine, E; Ho, DD; Horn, T; Irvine, B; Kolberg, J; Shen, LP; Tyner, D; Urdea, MS; Zayati, C1
Faulds, D; Jarvis, B1
Jackson, RC1
Butcher, D; Duong, P; Greene, J; Markson, L1
Duncombe, C1
Aladdin, H; Dickmeiss, E; Gerstoft, J; Hede, A; Jørgensen, LB; Katzenstein, TL; Nielsen, C; Nielsen, H1
Adler, M; Cross, AP; Dunkle, LM; Elion, R; Kaul, S; Kelleher, T; Knupp, C1
Atkinson, B; Isaacson, J; Knowles, M; Mazabel, E; Patick, AK1
Arnedo, A; Gómez, CJ; Roca, B1
Apuzzo, L; Deetz, C; Eshleman, SH; Fields, C; Flexner, C; Gallant, JE; Heath-Chiozzi, M; Jackson, JB; Lewis, RH; Raines, CP; Sun, E1
Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R1
Mascolini, M1
Becker, MI; Harrigan, PR; Humar, A; Walmsley, SL; Zhang, M1
Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L1
Fitzgibbon, JE; Gaur, S; Janahi, M; John, JF; Walsman, SM; Whitley-Williams, P1
Bartlett, JA; Bucy, RP; Fiscus, SA; Gryszowska, V; Miralles, GD; Ottinger, J; Pruitt, SK; Sevin, AD; Silberman, M1

Reviews

3 review(s) available for nelfinavir and HIV

ArticleYear
Peptidomimetic inhibitors of HIV protease.
    Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane

2004
Nelfinavir. A review of its therapeutic efficacy in HIV infection.
    Drugs, 1998, Volume: 56, Issue:1

    Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Drug Tolerance; HIV; HIV Infections; Humans; Nelfinavir

1998
[Resistance to protease inhibitors].
    Enfermedades infecciosas y microbiologia clinica, 2001, Volume: 19, Issue:Monografic

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides

2001

Trials

11 trial(s) available for nelfinavir and HIV

ArticleYear
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
    Clinical and diagnostic laboratory immunology, 2002, Volume: 9, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Nelfinavir; Oxazines; Random Allocation; RNA, Messenger; Stavudine; Treatment Failure

2002
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jan-01, Volume: 32, Issue:1

    Topics: Adult; Atazanavir Sulfate; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Stavudine; Time Factors; Viral Load

2003
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
    The Journal of infectious diseases, 2003, Apr-01, Volume: 187, Issue:7

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure

2003
Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infections; Nelfinavir; Prospective Studies; RNA, Viral; Salvage Therapy; Transcription Factors

2003
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
    The Journal of infectious diseases, 2004, Apr-01, Volume: 189, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Sex Factors

2004
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
    Journal of acquired immune deficiency syndromes (1999), 2007, Aug-15, Volume: 45, Issue:5

    Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine

2007
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
    Clinical pharmacokinetics, 2007, Volume: 46, Issue:11

    Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load

2007
The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Clinical therapeutics, 1999, Volume: 21, Issue:11

    Topics: Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; RNA, Viral; Safety; Stavudine; Treatment Outcome; Viral Load

1999
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    AIDS research and human retroviruses, 2001, Jan-20, Volume: 17, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Viral Load

2001
Phase II/III Trials of Viracept start.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:3

    Topics: Anti-HIV Agents; Blood; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine; Sulfonic Acids; Time Factors; Zidovudine

1996
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
    AIDS research and human retroviruses, 2002, May-20, Volume: 18, Issue:8

    Topics: Adolescent; Adult; CD4 Lymphocyte Count; Cyclophosphamide; DNA, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lymphoid Tissue; Male; Middle Aged; Monocytes; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load

2002

Other Studies

33 other study(ies) available for nelfinavir and HIV

ArticleYear
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
    Chemistry & biology, 1998, Volume: 5, Issue:10

    Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication

1998
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Bioorganic & medicinal chemistry letters, 2004, Feb-23, Volume: 14, Issue:4

    Topics: Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Multiple, Viral; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Molecular Structure; Mutation; Rats; Structure-Activity Relationship; Sulfonamides

2004
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Bioorganic & medicinal chemistry letters, 2005, Aug-01, Volume: 15, Issue:15

    Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication

2005
Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
    Bioorganic & medicinal chemistry letters, 2007, Aug-01, Volume: 17, Issue:15

    Topics: Amides; Cell Line; Cysteine; HIV; HIV Protease Inhibitors; Humans; Models, Molecular; Phenylbutyrates; Thiazoles

2007
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:8

    Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; HIV; HIV Integrase Inhibitors; Humans; Indoles; Integrases; Molecular Structure; Polymerase Chain Reaction; Viral Proteins; Virus Replication

2008
Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase.
    BMC research notes, 2018, Nov-21, Volume: 11, Issue:1

    Topics: Anti-HIV Agents; Aspartic Acid Proteases; Atazanavir Sulfate; Crystallography, X-Ray; Databases, Protein; Drug Repositioning; HIV; Molecular Docking Simulation; Nelfinavir; Peptide Hydrolases; Protease Inhibitors; Protein Conformation; Saccharomyces cerevisiae Proteins; Saquinavir; Trypanosoma cruzi

2018
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
    Current molecular medicine, 2015, Volume: 15, Issue:10

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine

2015
Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
    Journal of enzyme inhibition and medicinal chemistry, 2009, Volume: 24, Issue:3

    Topics: Amino Acid Sequence; Binding Sites; Drug Resistance, Viral; Enzyme Activation; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Microbial Viability; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Ritonavir; Sequence Alignment

2009
CD4 responses in the setting or suboptimal virological responses to antiretroviral therapy: features, outcomes, and associated factors.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:7

    Topics: Adult; CD4 Antigens; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Treatment Outcome; Viral Load

2009
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
    Journal of acquired immune deficiency syndromes (1999), 2011, Nov-01, Volume: 58, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nelfinavir; Nevirapine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Selection, Genetic

2011
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
    Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:9

    Topics: Adult; Drug Resistance; Female; Genes, Viral; Genotype; HIV; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV Seropositivity; Humans; Male; Middle Aged; Mutation; Nelfinavir

2002
Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:4

    Topics: Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Drug Interactions; HIV; HIV Infections; Humans; Infant; Male; Mycobacterium tuberculosis; Nelfinavir; Rifampin; Ritonavir; RNA, Viral; Tuberculosis, Pulmonary; Viral Load

2003
Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
    Antiviral therapy, 2003, Volume: 8, Issue:3

    Topics: Adolescent; Body Surface Area; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Nelfinavir; Retrospective Studies; RNA, Viral

2003
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2003, Dec-15, Volume: 34, Issue:5

    Topics: Biotransformation; Cohort Studies; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Time Factors; Treatment Failure; Viral Load

2003
Instrumental variables and interactions in the causal analysis of a complex clinical trial.
    Statistics in medicine, 2007, Mar-30, Volume: 26, Issue:7

    Topics: Anti-HIV Agents; Child; Data Interpretation, Statistical; Female; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Models, Statistical; Nelfinavir; Patient Compliance; Randomized Controlled Trials as Topic; RNA, Viral

2007
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4

    Topics: Amino Acid Substitution; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation; Nelfinavir; Polymerase Chain Reaction; Sensitivity and Specificity

2007
Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.
    Antiviral therapy, 2007, Volume: 12, Issue:5

    Topics: Cell Line; Cytopathogenic Effect, Viral; DNA Mutational Analysis; Drug Resistance, Viral; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutation; Nelfinavir; Verapamil; Virus Replication

2007
HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Antiviral therapy, 2007, Volume: 12, Issue:6

    Topics: Adult; Algorithms; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Viral Load

2007
Anti-HIV effects of Viracept persist during long periods of combination therapy.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:6

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Safety; Sulfonic Acids

1997
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.
    Nucleic acids research, 1997, Aug-01, Volume: 25, Issue:15

    Topics: Adenosine; Anti-HIV Agents; Cytidine; DNA; DNA, Viral; Drug Therapy, Combination; Guanosine; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Nelfinavir; Nucleic Acid Hybridization; RNA, Viral; Sulfonic Acids; Zidovudine

1997
A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity.
    Journal of pharmacokinetics and biopharmaceutics, 1997, Volume: 25, Issue:6

    Topics: Anti-HIV Agents; CD4-CD8 Ratio; Dose-Response Relationship, Drug; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Models, Theoretical; Nelfinavir; Zidovudine

1997
Virologic response associated with a change in protease inhibitor therapy.
    Archives of internal medicine, 2000, Feb-14, Volume: 160, Issue:3

    Topics: HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Treatment Outcome

2000
Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir.
    Journal of acquired immune deficiency syndromes (1999), 2000, May-01, Volume: 24, Issue:1

    Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lipodystrophy; Nelfinavir; Prospective Studies

2000
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
    Annals of internal medicine, 2000, Jul-04, Volume: 133, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Transfusion Reaction; Zidovudine

2000
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    The Journal of infectious diseases, 2000, Volume: 182, Issue:2

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine

2000
Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    The Journal of infection, 2000, Volume: 41, Issue:1

    Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Logistic Models; Male; Nelfinavir; Patient Compliance; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Statistics, Nonparametric; Stavudine; Substance Abuse, Intravenous

2000
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
    Journal of acquired immune deficiency syndromes (1999), 2000, Dec-01, Volume: 25, Issue:4

    Topics: Adult; Chromatography, High Pressure Liquid; Cohort Studies; DNA, Viral; Female; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; Sequence Analysis, DNA; Viral Load

2000
Protease inhibitor trials moving to next phase.
    AIDS alert, 1995, Volume: 10, Issue:8

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication

1995
Agouron protease inhibitor.
    AIDS treatment news, 1995, Sep-29, Issue:no 231

    Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir

1995
Closing the circle on HIV--or not.
    Journal of the International Association of Physicians in AIDS Care, 1995, Volume: 1, Issue:9

    Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Nelfinavir; Prognosis; RNA, Viral; Zalcitabine; Zidovudine

1995
Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir.
    Antiviral therapy, 2001, Volume: 6, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Genotype; HIV; HIV Infections; Humans; Male; Nelfinavir; RNA, Viral; Salvage Therapy

2001
Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
    AIDS research and human retroviruses, 2001, Sep-20, Volume: 17, Issue:14

    Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Nelfinavir; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral

2001
Nelfinavir (Viracept).
    Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:1

    Topics: Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Practice Guidelines as Topic

2000